60 Degrees Pharmaceuticals, Inc.
SXTP Nasdaq
SEC CIK 1946563
Follow 60 Degrees Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$233.2K
−46.7% vs same quarter last year
Net income
−$2.6M
−10.4% vs same quarter last year
EPS, diluted
−$0.75
+71.8% vs same quarter last year
Operating cash flow
−$1.4M
+31.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1M | −$7.4M |
| FY24 | $607.6K | −$7.9M |
| FY23 | $253.6K | −$3.8M |
| FY22 | $223.2K | −$6.2M |
| FY21 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 22.3% | −771.6% | −732.5% |
| FY24 | 36.7% | −1599% | −1308% |
| FY23 | −87.1% | −2032.8% | −1485.1% |
| FY22 | −93.7% | −784.2% | −2769.5% |
| FY21 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$7M |
| FY24 | −$5.8M |
| FY23 | −$4.6M |
| FY22 | - |
| FY21 | - |
- 60 Degrees Pharmaceuticals
- Healthcare median
Show the numbers
| Year | 60 Degrees Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −732.5% | −30.6% |
| FY24 | −1308% | −47% |
| FY23 | −1485.1% | −58% |
| FY22 | −2769.5% | −80.4% |
| FY21 | - | −71.9% |